Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

‘Solid’ start for Novartis

April 30, 2013
Sales and Marketing Novartis, Q1, sales

Novartis’ sales of pharma products were unchanged in the first quarter of 2013 at $7.9 billion, with pricing flat, the …

News

EU approval for Ilaris

March 4, 2013
Sales and Marketing Ilaris, Novartis

Novartis’ Ilaris has become the first biologic approved by the European Commission to treat patients suffering acute gouty arthritis attacks …

News

Vasella forgoes golden handshake after furore

February 19, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Vasella

Novartis has backed down over plans to pay outgoing chairman Dr Daniel Vasella a ‘golden handshake’ worth $77 million (72 …

News
novartis image

Another approval for Novartis’ everolimus

February 18, 2013
Sales and Marketing Certican, Novartis, Zortress, everolimus

Novartis has gained US approval for its drug Zortress (everolimus) to prevent liver transplant rejection.Zotress is already used to prevent …

News
novartis image

Novartis’ Nebraska OTC plant still troubles company

February 11, 2013
Manufacturing and Production Novartis, OTC

Novartis has been forced to recall various over-the-counter (OTC) medicines made at its plant in Lincoln, Nebraska, after discovering failures …

News
Roche image

Facility of the year: 2013 winners announced

February 4, 2013
Manufacturing and Production Biogen, MedImmune, Merck, Novartis, Roche

Three US and three European manufacturing plants have been selected as category winners for the annual Facility of the Year …

News

NICE recommends two cystic fibrosis treatments

January 25, 2013
Sales and Marketing Colobreath, Forest Labs, Novartis, Tobi Podhaler, cystic fibrosis

NICE has given final recommendation to two new inhalers for cystic fibrosis (CF) patients.Forest Lab’s Colobreath (colistimethate sodium) and Novartis’ …

News

Novartis’ 2012 results flat

January 24, 2013
Sales and Marketing Bexsero, Jakavi, Novartis, generics, results

Generic competition has put a dent in Novartis’ financial results for 2012, with net sales down 3% year on year …

News

Jörg Reinhardt to leave Bayer for Novartis

January 24, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Novartis, Reinhardt

The chairman of the Board and member of the Bayer executive council Dr Jörg Reinhard is stepping down from his …

Appointment
novartis image

EU approval for meningitis vaccine

January 23, 2013
Sales and Marketing Bexsero, CHMP, Novartis, meningitis

European regulators have approved Novartis’ Bexsero, making it the first broad coverage vaccine to target the leading cause of meningitis. …

News
Novartis image

Novartis eye drug nears approval

January 21, 2013
Sales and Marketing AMD, CHMP, Jetria, Novartis

Novartis’ eye drug Jetrea has been given a positive opinion by the CHMP, pushing it to the brink of approval. …

News
Eisai image

Eisai and Novartis part ways

January 8, 2013
Sales and Marketing COPD, Eisai, Novartis, Onbrez, Spiriva

Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …

News
lucentis

New price and data changes NICE view on Lucentis

January 4, 2013
Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis

A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …

News

Signifor approved in US

December 17, 2012
Sales and Marketing Cushing's, Novartis, Signifor

Novartis’ injection Signifor has been approved by the FDA to treat Cushing’s disease, a rare but serious endocrine disorder affecting …

News
novartis_window

Novartis blood cancer hope

December 12, 2012
Research and Development, Sales and Marketing Jakavi, Novartis, oncology

Two-year data from Novartis’s drug Jakavi suggests that it may improve overall survival in a rare form of cancer versus …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025